Andrew Splevins

Andrew Splevins is an experienced professional in the field of CMC and Project Leadership, with a background in Analytical Sciences and Bioprocess Development. Andrew has held various leadership roles in companies such as Evox Therapeutics Ltd, Ipsen, Syntaxin Ltd, Patheon Inc., and Covance. Andrew holds a PhD in Biochemistry, Biophysics, and Molecular Biology, as well as an MChem in Biological Chemistry from The University of Sheffield. Their expertise lies in leading teams to develop novel genetic medicines, accelerating product development, and taking unique modalities into clinical trials.